Christos Fountzilas
Roswell Park Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christos Fountzilas as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:15 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07214298 · Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal AdenocarcinomaRoswell Park Cancer Institute · recruiting · Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 · principal investigator
- Ph2NCT06821997 · NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar TrialRoswell Park Cancer Institute · recruiting · Borderline Resectable Pancreatic Ductal Adenocarcinoma · principal investigator
- Ph1NCT06206876 · FL118 for Treating Patients With Advanced Pancreatic Ductal AdenocarcinomaRoswell Park Cancer Institute · withdrawn · Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma · principal investigator
- Early Ph1NCT04870034 · Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerRoswell Park Cancer Institute · withdrawn · Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Neoplasm · principal investigator
- Ph1NCT04511039 · Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal CancerRoswell Park Cancer Institute · recruiting · Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma · principal investigator
- Ph2NCT04119830 · Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal CancerRoswell Park Cancer Institute · withdrawn · Metastatic Colorectal Adenocarcinoma, Microsatellite Stable, Mismatch Repair Proficient · principal investigator
- Ph2NCT04109924 · TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO StudyRoswell Park Cancer Institute · completed · Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma · principal investigator
- Ph1/Ph2NCT02713373 · Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by SurgeryRoswell Park Cancer Institute · completed · Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer · principal investigator
- Ph1/Ph2NCT02393755 · Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal CancerRoswell Park Cancer Institute · completed · Colon Adenocarcinoma, Rectal Adenocarcinoma, Recurrent Colon Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Novel synthetic lethality strategy for TP53 mutant colorectal cancerR37CA282430 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2023 to 2026 · $510,841 awarded in 2026Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Administrative CoreP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dale Henry · fiscal years 2008 to 2026Named on NCT02713373, NCT02393755
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 13:15 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.Clin Cancer Res · 2020160 citationsRCR 6.2
- 49 citationsRCR 5.5
- A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.Clin Cancer Res · 202427 citationsRCR 3.0
- Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.N Engl J Med · 202624 citationsRCR 12.0
- 21 citationsRCR 4.8
- A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent.Cancer Chemother Pharmacol · 201711 citationsRCR 0.4
- Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.Oncologist · 20243 citationsRCR 0.5